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THROMBOLYSIS OUTCOMES IN ACUTE ISCHEMIC STROKE PATIENTS WITH PRIOR STROKE AND DIABETES MELLITUS
Gaetano Santulli, New York: Mishra et al. 1 examined the influence of diabetes mellitus and prior stroke on the outcomes of patients who received thrombolysis vs nonthrombolyzed controls. They found no interaction on outcome between diabetes and prior stroke with thrombolysis treatment.
These results conflict with the European Medicines Evaluation Agency's justification for restricting the use of IV alteplase. As Dr. Demaerschalk mentioned in the accompanying editorial, 2 recent studies 1,3,4 have suggested that thrombolysis can be safely used in several groups of patients who do not qualify for treatment due to strict application of exclusion criteria.
In addition, most of the commonly cited thrombolytic exclusion criteria are just consensus-based, not evidence-based. 2, 3 It is time to reevaluate the criteria for thrombolysis, adopting a clinical score to stratify the risk, similar to those used in acute coronary syndrome. 5 A good risk assessment tool will be able to identify a gradient of mortality risk by using variables that capture the majority of prognostic information to better evaluate the risk/benefit ratio for each patient.
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A RANDOMIZED TRIAL OF HIGH-DOSE VITAMIN D2 IN RELAPSING-REMITTING MULTIPLE SCLEROSIS
Helmut H. Leitner, Vienna: Stein et al. 1 compared high-vs low-dose vitamin D2 treatment in MS without benefit in the high-dose treatment group. Sunlight exposure and reduced vitamin D3 levels independently contribute to MS risk. The effect of sunlight exposure is supported by decreased signs of actinic skin damage found in MS patients compared to controls. 2 It is difficult to determine which of these 2 environmental factors is of primary importance as higher levels of sunlight exposure will enhance vitamin D levels.
The incidence of vitamin D-related rickets disease decreased in the United States and Europe during the last century following the discovery that vitamin D possessed antirachitic properties, whereas the incidence of MS seemed to increase in the same population. In the United States, most of the patients with rickets are African American, whereas the majority of patients with MS are of European ancestry. 3 It seems improbable that the same environmental factor should be centrally involved in the etiology of both diseases, which differ clinically and occur in different populations living in the same geographic area.
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